These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8506311)

  • 1. Immunotherapy of malignancy by in vivo gene transfer into tumors.
    Plautz GE; Yang ZY; Wu BY; Gao X; Huang L; Nabel GJ
    Proc Natl Acad Sci U S A; 1993 May; 90(10):4645-9. PubMed ID: 8506311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenoviral transfer of xenogeneic MHC class I gene results in loss of tumorigenicity and inhibition of tumor growth.
    Campbell I; Moyana T; Carlsen S; Zheng C; Xiang J
    Cancer Gene Ther; 2000 Jan; 7(1):37-44. PubMed ID: 10678354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene.
    Hui KM; Sim T; Foo TT; Oei AA
    J Immunol; 1989 Dec; 143(11):3835-43. PubMed ID: 2584720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct gene transfer for treatment of human cancer.
    Nabel GJ; Yang ZY; Nabel EG; Bishop K; Marquet M; Felgner PL; Gordon D; Chang AE
    Ann N Y Acad Sci; 1995 Nov; 772():227-31. PubMed ID: 8546397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
    Merritt RE; Yamada RE; Crystal RG; Korst RJ
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased sensitivity to MHC-nonrestricted lysis of BL6 melanoma cells by transfection with class I H-2Kb gene.
    Gorelik E; Jay G; Kwiatkowski B; Herberman RB
    J Immunol; 1990 Sep; 145(5):1621-32. PubMed ID: 2384672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
    Xiang J; Chen Y; Moyana T
    Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic MHC gene transfer enhances an effective antitumor immunity in the early period of autologous hematopoietic stem cell transplantation.
    Kobayashi A; Hara H; Ohashi M; Nishimoto T; Yoshida K; Ohkohchi N; Yoshida T; Aoki K
    Clin Cancer Res; 2007 Dec; 13(24):7469-79. PubMed ID: 18094431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of melanoma-associated antigen expression and ecotropic retrovirus production in B16BL6 melanoma cells transfected with major histocompatibility complex class I genes.
    Li M; Muller J; Xu F; Hearing VJ; Gorelik E
    Cancer Res; 1996 Oct; 56(19):4464-74. PubMed ID: 8813142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor effect associated with down-regulation of MHC class 1 antigen after co-transfection of GM-CSF and IFN-gamma genes in CT26 tumor cells.
    Yoon SJ; Lee JC; Kang JO; Lee SG; Heo DS
    Anticancer Res; 2001; 21(6A):4031-9. PubMed ID: 11911288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrovirus-induced changes in major histocompatibility complex antigen expression influence susceptibility to lysis by cytotoxic T lymphocytes.
    Flyer DC; Burakoff SJ; Faller DV
    J Immunol; 1985 Oct; 135(4):2287-92. PubMed ID: 2411792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
    Imboden M; Murphy KR; Rakhmilevich AL; Neal ZC; Xiang R; Reisfeld RA; Gillies SD; Sondel PM
    Cancer Res; 2001 Feb; 61(4):1500-7. PubMed ID: 11245457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells.
    Kikuchi T; Crystal RG
    Hum Gene Ther; 1999 May; 10(8):1375-87. PubMed ID: 10365667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotype.
    Lu X; Kallinteris NL; Li J; Wu S; Li Y; Jiang Z; Hillman GG; Gulfo JV; Humphreys RE; Xu M
    Cancer Immunol Immunother; 2003 Oct; 52(10):592-8. PubMed ID: 12827305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination gene transfer to potentiate tumor regression.
    Ohno T; Yang Z; Ling X; Jaffe M; Nabel EG; Normolle D; Nabel GJ
    Gene Ther; 1997 Apr; 4(4):361-6. PubMed ID: 9176523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of tumour-specific immunity by manipulating the expression of major histocompatibility complex molecules on tumour cells.
    Hui KM
    FEMS Microbiol Immunol; 1990 Nov; 2(4):215-21. PubMed ID: 2285518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.
    Abrams SI; Stanziale SF; Lunin SD; Zaremba S; Schlom J
    Eur J Immunol; 1996 Feb; 26(2):435-43. PubMed ID: 8617315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combination therapy of experimental murine hepatoma with mIL-12 gene and MHC I gene mediated by liposome].
    Wang KM; Xia AD; Chen SS
    Ai Zheng; 2002 Oct; 21(10):1041-6. PubMed ID: 12508639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphological transformation, tumorigenicity and src-specific cytotoxic T-lymphocyte-mediated tumor immunity induced by murine 3T3 cells expressing src oncogenes encoding novel non-myristylated N-terminal domains.
    Gelman IH; Khan S; Hanafusa H
    Oncogene; 1993 Nov; 8(11):2995-3004. PubMed ID: 7692370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.